Predictors of time in target glucose range in real‐world users of the MiniMed 780G system
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Aim: Automated insulin delivery systems have improved glycaemic control in people with type 1 diabetes mellitus. The analysis investigated predictors of improved sensor glucose time‐in‐range (TIR; 70‐180 mg/dl) based on real‐world use of the MiniMed 780G advanced hybrid closed‐loop (AHCL) system. Methods: Data uploaded by MiniMed 780G system users from August 2020‐July 2021 were analysed using univariate and multivariable models to identify baseline, demographic and system use characteristics associated with TIR after AHCL initiation (post‐AHCL). System settings associated with improved TIR post‐AHCL were identified and their impact on time below range (TBR, <70 mg/dl) post‐AHCL was explored. Results: In total, 12 870 users were included, of which 2977 had baseline sensor glucose data. Baseline TIR and time in AHCL (defined as the percentage of time the system was in Auto‐mode) were positively associated with TIR post‐AHCL with larger values predicting greater mean TIR post‐AHCL. Characteristics inversely associated with TIR post‐AHCL included the percentage of daily basal insulin dose, daily autocorrection dose, number of daily AHCL exits triggered by the system and number of daily alarms, wherein larger values of these characteristics predicted lower mean TIR post‐AHCL. System settings that predicted the largest mean TIR post‐AHCL were active insulin time of 2 h and glucose target of 100 mg/dl. Active insulin time was not associated with TBR post‐AHCL. Conclusion: Modifiable factors, including optimized pump settings, can allow users to achieve glycaemic targets with >80% TIR. The findings from this analysis will potentially guide the optimal use of the MiniMed 780G system and facilitate meaningful improvements in safe glycaemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237 · cited 1×
“0%, well below the recommended threshold of 4%.(8) When the target was set at 100 mg/dl (5.”
BackgroundSelf-citation6. Glycemic Targets: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s006 · Cited by 1,403
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“The recommended target of 100 mg/dl is also proposed for the majority of users, while a target of 110 mg/dl is recommended in the following situations: (a) age <15 years;(17) (b) when concerned about exacerbation of retinopathy when glucose levels are reduced rapidly (may use target of 120 mg/dl)(26); and (c) presence…”
Background6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4127 · Cited by 412
Bergenstal, R. M., Nimri, R., Beck, R. W., Criego, A., Laffel, L., Schatz, D., Battelino, T., Danne, T., Weinzimer, S. A., Sibayan, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32514-9 · Cited by 344
Carlson, A. L., Sherr, J. L., Shulman, D. I., Garg, S. K., Pop-Busui, R., Bode, B. W., Lilenquist, D. R., Brazg, R. L., Kaiserman, K. B., Kipnes, M. S., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0319 · Cited by 230
Self-citationReal-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users
Silva, J. D., Lepore, G., Battelino, T., Arrieta, A., Castañeda, J., Grossman, B., Shin, J., & Cohen, O. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0203 · Cited by 229
Self-citationCardona-Hernandez, R., Schwandt, A., Alkandari, H., Bratke, H., Chobot, A., Coles, N., Corathers, S., Goksen, D., Goss, P., Imane, Z., et al. (2021) · Diabetes Care · doi:10.2337/dc20-1674 · Cited by 129
Cited by
Petrovski, G., Campbell, J., Pasha, M., Day, E., Hussain, K., Khalifa, A., & van den Heuvel, T. (2023) · Diabetes Care · doi:10.2337/dc22-1692 · Cited by 108
“These settings are known to be predictors for a higher TIR and most probably are attributed to the high TIR (18).”
BackgroundCastañeda, J., Arrieta, A., van den Heuvel, T., Battelino, T., & Cohen, O. (2024) · Diabetes Care · doi:10.2337/dc23-1581 · Cited by 107
“For instance, randomized controlled studies (8,9) and real-world evidence (10,11) have demonstrated that users of the MiniMed 780G (MM780G) advanced hybrid closed-loop (AHCL) system can achieve an average TIR > 80% without increased risk of hypoglycemia, when users consistently use optimal system…”
BackgroundMethodResultSelf-citationForlenza, G. P., DeSalvo, D. J., Aleppo, G., Wilmot, E. G., Berget, C., Huyett, L. M., Hadjiyianni, I., Méndez, J. J., Conroy, L. R., Ly, T. T., et al. (2024) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2023.0578 · Cited by 99
The role of automated insulin delivery technology in diabetes
Boughton, C. K., & Hovorka, R. (2024) · Diabetologia · doi:10.1007/s00125-024-06165-w · Cited by 57
Chico, A., Navas de Solís, S., Lainez, M., Rius, F., & Cuesta, M. (2023) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0449 · Cited by 14
Metadata
- Authors
- Castañeda, J., Mathieu, C., Aanstoot, H., Arrieta, A., Da Silva, J., Shin, J., & Cohen, O.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2022-08
- Volume
- 24
- Issue
- 11
- Pages
- 2212-2221
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4283837006
- Cited by
- 106
- References
- 9
- FWCI
- 13.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.